Johnson & Johnson Opioid Business Ended in a $230 Million Settlement
Johnson & Johnson has agreed to a $230 million settlement with the state of New York, which prohibits the company from promoting opioids and confirms it has discontinued distribution of such medications in the United States.
New York Opioid Epidemic
The office of New York Attorney General Letitia James said in a statement Saturday that the deal prevents J&J from advertising opioids in any way and from lobbying about such products at the federal, state, or municipal level.
Johnson & Johnson discontinued the marketing of opioids in the United States in 2015 and fully refrained from the business in 2020.
The company will address opioid-related claims and distribute payments over a nine-year period as part of the settlement. Additionally, it could pay an additional $30 million in the first year if the state executive chamber passes new legislation creating an opioid settlement fund, according to a press release from James’ office.
The Johnson & Johnson Opioid Settlement 2021 comes after years of lawsuits between states, cities, counties, and major pharmaceutical companies over the opioid epidemic, claiming roughly 500,000 lives in the United States over the last two decades.
Governments have stated that companies overprescribed the drugs, resulting in people developing an addiction and abusing other illegal varieties of opioids. In contrast, companies have claimed that they provided the appropriate amount of the drug to assist people with medical issues.
The opioid epidemic has devastated countless communities throughout New York State and the rest of the country, leaving millions addicted to harmful and deadly narcotics, James said in a statement.
In addition, she said that Johnson & Johnson helped to fuel the fire but is now committing to quit the opioid business – not just in New York but nationwide. The company will cease manufacturing and selling opioids in the United States.
According to the statement, the trial against the remaining defendants in the New York opioid lawsuit will start on Tuesday. Other defendants in the New York lawsuit include:
- Allergan Finance LLC
- Endo Health Solutions
- Mallinckrodt LLC
- Purdue Pharma, and
- Teva Pharmaceuticals USA
Johnson & Johnson stated on Saturday that the Johnson & Johnson Opioid Settlement 2021 does not imply an admission of liability or negligence by the company. It also indicated that it is consistent with the previously announced $5 billion all-in settlement agreement in principle to settle opioid lawsuits and claims brought by states, cities, counties, and tribal governments.
Moreover, the company stated that it would continue to defend itself against any lawsuits not resolved by the final agreement.
James stated that the state would prioritize opioid prevention, treatment, and education to avoid further devastation.
Along with the James’ class action lawsuit, the company has been named as a defendant in a number of other class actions over the years — including lawsuits alleging that Johnson & Johnson’s baby powder contains asbestos and causes cancer, as well as allegations of faulty surgical staples.
Editor’s Note on Johnson & Johnson Opioid Settlement 2021:
This is written to inform you of Johnson & Johnson’s opioid business in New York that ended in a $230 million settlement.
Case Name & No.: Letitia James, Attorney General of the State of New York v. Johnson & Johnson, 2021
Jurisdiction: Supreme Court of the State of New York County of Suffolk
Products/Services: Johnson & Johnson’s Opioids
Allegations: Johnson & Johnson’s product contains opioids resulting in people getting addicted
Are you using products made by Johnson & Johnson? What are your thoughts about the verdict? Share your thoughts with us; click the “Contact Us” button below!
Suggested Article: Philips Ventilator Recall Class Action Lawsuit 2021.